达雷妥尤单抗与伊沙妥昔单抗对骨髓瘤浆细胞CD38检测的差异影响:抗CD38纳米抗体(克隆JK36)与CD319联合应用改善靶向治疗后浆细胞的流式细胞术识别
该研究验证了一种11色浆细胞流式Panel,除常用门控标志物(CD45、CD38、CD138)外,纳入CD319和抗CD38单可变重链结构域纳米抗体(克隆JK36),并采用布尔「或」功能联合门控浆细胞。在达雷妥尤单抗治疗样本中,异常浆细胞CD38(克隆HB-7)表达丢失,JK36在几乎所有此类病例中克服了达雷妥尤单抗的阻断;伊沙妥昔单抗则呈现相反模式,JK36检测CD38完全丢失,而HB-7保留弱阳性。该标志物组合在CD38靶向治疗后识别异常浆细胞方面高度有效,支持流式Panel中门控标志物冗余的必要性。
要点
- 达雷妥尤单抗导致异常浆细胞CD38(克隆HB-7)表达丢失,JK36在几乎所有病例中克服其阻断。
- 伊沙妥昔单抗呈现相反模式:JK36检测CD38完全丢失,HB-7保留弱阳性。
- CD319与JK36联合门控可提高CD38靶向治疗后异常浆细胞的流式识别效果。
核心结论
- 达雷妥尤单抗与伊沙妥昔单抗对CD38检测的影响模式不同,JK36与CD319联合门控可改善CD38靶向治疗后浆细胞的流式细胞术识别。
研究设计与样本
- 验证一种11色浆细胞流式Panel,除CD45、CD38、CD138外纳入CD319和抗CD38纳米抗体克隆JK36,并采用布尔「或」功能联合门控浆细胞。
- 比较接受达雷妥尤单抗、伊沙妥昔单抗或均未接受治疗的患者样本中抗原表达模式与强度。
主要发现
- 达雷妥尤单抗导致异常浆细胞CD38(克隆HB-7)可检测表达丢失,JK36在几乎所有此类病例中克服达雷妥尤单抗阻断。
- 伊沙妥昔单抗呈现相反模式:JK36检测CD38完全丢失,而HB-7保留弱阳性。
- 该标志物组合在CD38靶向治疗后识别异常浆细胞方面高度有效。
关键数值与推荐
- 11色Panel包含CD45、CD38、CD138、CD319及抗CD38纳米抗体克隆JK36。
- 采用布尔「或」功能联合上述标志物门控浆细胞。
临床怎么用
- 原文结论支持流式细胞术Panel中门控标志物冗余的必要性,以应对CD38靶向治疗后的检测干扰。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Inclusion of daratumumab and isatuximab in therapeutic regimens has improved outcomes in multiple myeloma patients. As these agents block CD38 detection, they may result in difficulties in flow cytometric (FC) identification of plasma cells (PCs). In addition, the heterogeneity of myeloma immunophenotype and the introduction of novel therapeutic agents necessitate FC panels with robust gating markers. To this end, we validated an 11-colour PC panel that in addition to commonly used gating markers (CD45, CD38, CD138) includes CD319 and anti-CD38 single variable heavy domain nanobody (clone JK36). A Boolean "or" function was applied to gate PCs using a combination of the above markers. Patterns and intensity of antigen expression were compared in samples from patients receiving daratumumab or isatuximab therapy, or neither. Daratumumab resulted in loss of detectable CD38 expression (clone HB-7) on abnormal PCs, and JK36 overcame daratumumab blockage in almost all these cases. Interestingly, isatuximab showed an opposite pattern, with complete loss of CD38 detection by JK36, while retaining dim positivity by HB-7. This combination of markers proved highly effective in identifying abnormal PCs after CD38-directed therapies, supporting a need for redundancy of gating markers in FC panels.
引用
- Shameli A, Catey T, Woodings V, et al. Daratumumab and isatuximab differentially affect CD38 detection on plasma cells in myeloma: Anti-CD38 nanobody (clone JK36) and CD319 combination improve flow cytometric identification of plasma cells after targeted therapies. Br J Haematol. 2025. PMID: 40538116. doi:10.1111/bjh.20218
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。